Kailera Therapeutics
Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on the next generation of obesity and cardiometabolic care through a diversified pipeline of GLP-1 based therapies. Founded in 2024 and headquartered in Waltham, Massachusetts, its lead candidate ribupatide (KAI-9531) is a once-weekly injectable GLP-1/GIP receptor dual agonist in a global Phase 3 program, alongside oral small-molecule GLP-1 candidates and tri-agonist programs licensed in part from Jiangsu Hengrui Pharmaceuticals. Kailera has raised a $400M Series A and a $600M Series B led by Bain Capital, and priced its IPO in April 2026 (NASDAQ: KLRA). This is a corporate/portfolio company profile in the API Evangelist network; Kailera publishes no public developer API surface.
More than an index entry, but the surface is still mostly links rather than artifacts — the cohort most likely to move a full band from modest, well-targeted work.
API Evangelist profiles Kailera Therapeutics the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Kailera Therapeutics scores 15.0/100 (emerging), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Kailera Therapeutics
Each block below is one kind of artifact we hold for Kailera Therapeutics. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Kailera Therapeutics — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 5
The organization behind the API
← All providers · Data indexed from github.com/api-evangelist/kailera-therapeutics · machine-readable index on apis.io